IL1B and peritonitis: In patients suffering from an interleukin-1 (IL-1) driven inflammatory disease, continuation of IL-1 inhibition is important because inflammation in these diseases is not controlled by the standard immunosuppressive drugs used after renal transplantation, and when anti-IL-1 directed therapy is stopped these patients are at high risk of recurrence of inflammation, associated with severe symptoms, such as arthritis, peritonitis, meningitis and many others.